The company plans to start clinical development next year. Its focus is on bispecific antibodies - a form of cancer immunotherapy - that use gamma-delta "surveillance" T cells.
Versant Ventures' latest startup Jecure debuted on Wednesday with a $20M Series A to further its preclinical work in liver fibrosis and NASH.
The layout of your phlebotomy station can significantly impact efficiency. A well-thought-out setup ensures that every tool is within reach, minimizing unnecessary movement and reducing patient wait times.
Like deadly paratroopers descending from the skies, Tarveda's Pentarin drug conjugates are designed to infiltrate dense tumors, triggering a controlled cell death as they are internalized or bound. It's an ADC variation that's gaining momentum and cash.
A startup from the Scripps Research Institute has raised a $50 million Series A to "expand the druggable proteome." Led by ARCH and Versant Ventures, the sizeable investment reflects the potential of both the platform and the countless therapeutic candidates it could produce.